Ivan Melezínek


Ivan graduated from Medical School of the Charles University in Prague, where he also defended his PhD in the area of tumor associated antigens at the Institute of Medical Chemistry and Biochemistry. Since 1991 he worked in drug research and development for renowned international pharmaceutical companies, e.g. AstraZeneca, Hofmann LaRoche or Merck KGaA, most of the time out of the Czech Republic.

He performed roles of a Medical Advisor up to a Cluster Leader level, part of his time was also devoted to Discovery. After leaving Merck, he was a Chief Medical Officer of EpiTherapeutics in Denmark and contributed to its sale to an American investor. Since 2014 Ivan is a consultant in the area of in-licensing and clinical development strategy. He also devotes his time to teaching oncology biochemistry at the Medical School of the Charles University.

Contact Me

This website uses cookies; by continuing to use this page, you consent to their use. About cookies